Here's What Key Metrics Tell Us About Amgen (AMGN) Q4 Earnings

For the quarter ended December 2025, Amgen (AMGN) reported revenue of $9.87 billion, up 8.6% over the same period last year. EPS came in at $5.29, compared to $5.31 in the year-ago quarter.The reported revenue represents a surprise of +4.23% over the Zacks Consensus Estimate of $9.47 billion. With the consensus EPS estimate being $4.76, the EPS surprise was +11.18%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Amgen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Product Sales- BLINCYTO- U.S.: $270 million versus $283.5 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.Product Sales- KYPROLIS- ROW: $111 million versus $130.37 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -18.4% change.Product Sales- Repatha- U.S.: $517 million compared to the $451.25 million average estimate based on six analysts. The reported number represents a change of +64.1% year over year.Product Sales- Repatha- ROW: $353 million versus $360.19 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +21.3% change.Revenue- Other revenues: $499 million compared to the $396.39 million average estimate based on eight analysts. The reported number represents a change of +34.9% year over year.Revenue- Product sales: $9.37 billion versus the eight-analyst average estimate of $9.09 billion. The reported number represents a year-over-year change of +7.5%.Product Sales- Otezla- Total: $625 million versus the seven-analyst average estimate of $621.09 million. The reported number represents a year-over-year change of +0.2%.Product Sales- KYPROLIS- Total: $351 million versus the seven-analyst average estimate of $362.31 million. The reported number represents a year-over-year change of -5.7%.Product Sales- BLINCYTO- Total: $413 million versus $435.33 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +8.4% change.Product Sales- Repatha- Total: $870 million versus $811.51 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +43.6% change.Product Sales- XGEVA- Total: $447 million versus $453.76 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -20.3% change.Product Sales- Prolia- Total: $1.05 billion versus $974.58 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -9.5% change.View all Key Company Metrics for Amgen here>>>Shares of Amgen have returned +7.5% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks